BioSpace News Archive

Drug Development

J&J Maintains Momentum in Multiple Myeloma with Tecvayli Approval

The FDA has greenlit the use of Johnson & Johnson’s Tecvayli in heavily pretreated adult patients with relapsed or refractory multiple myeloma.

October 26, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Oncopeptides Sees Redemption with Positive Multiple Myeloma Data after ODAC Vote

One month after a contentious FDA advisory meeting, Oncopeptides announced positive data from the Phase III LIGHTHOUSE trial of Pepaxto in RRMM patients.

October 26, 2022
·
2 min read
·
Mark Terry
Drug Development

AstraZeneca Scores Double Win in Breast Cancer with Two Mid-Stage Candidates

AstraZeneca released data Wednesday morning from two studies in breast cancer: the Phase III CAPItello-291 trial studying capivasertib and the Phase II SERENA-2 trial studying camizestrant.

October 26, 2022
·
3 min read
·
Alex Keown
FDA

FDA Adcomm Returns Mixed Vote on GSK’s CKD Drug - Updated

An FDA adcomm that met Wednesday to vote on GlaxoSmithKline’s daprodustat for adult patients with anemia due to chronic kidney disease (CKD) produced mixed results.

October 26, 2022
·
3 min read
·
Mark Terry
Drug Development

MS Drug Advances from Merck, BMS and More Showcased at ECTRIMS Conference

Merck, Bristol Myers Squibb, Biogen and others presented their latest data from MS programs at the 38th ECTRIMS conference.

October 26, 2022
·
2 min read
·
Kaley Lefevre
Policy

FDA’s ODAC Unanimously Votes against Y-mAbs’ Pediatric Neuroblastoma Treatment

The FDA’s Oncologic Drugs Advisory Committee voted unanimously against approving l-omburtamab for children with a rare form of neuroblastoma, citing complex review issues.

October 26, 2022
·
3 min read
·
Alex Keown and Heather McKenzie
VitroLabs Appoints Anthony Chow and Martin Avetisyan to its Board of Directors

VitroLabs Inc, the California based biotech company leading the commercialization of cell cultivated animal leather, announces the appointment of two new members to its Board of Directors

October 26, 2022
·
6 min read
Drug Development

Bridging the Translational Gap between Alzheimer’s Advances and Patients

With diagnostics for Alzheimer’s already approved and therapeutics in late-stage clinical trials, the next hurdle is to translate these advances into clinical practice. The Davos Alzheimer’s Collaborative is working on it.

October 26, 2022
·
7 min read
·
Gail Dutton
Biotech Beach

Complete Genomics, part of MGI, Announces Next-Generation Sequencing Platforms at ASHG Annual Meeting

Complete Genomics, part of MGI, celebrates the US commercial launch of their DNBSEQTM sequencing product line at the American Society of Human Genetics Annual Meeting, from October 25-29, in Los Angeles.

October 26, 2022
·
4 min read
Biotech Bay

Vaxcyte Announces Pricing of $600 Million Public Offering

Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced the pricing of an underwritten public offering of common stock and pre-funded warrants.

October 26, 2022
·
4 min read